RedHill Biopharma Completes Private Placement Financing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: PRnewswire
- Financing Scale: RedHill Biopharma has entered into a private placement for 8,571,429 American Depositary Shares (ADSs) at a purchase price of $0.70 per ADS, expecting to raise approximately $6 million, indicating strong market interest in the company.
- Potential Revenue: If the Series A-1 and A-2 warrants are fully exercised, RedHill could secure an additional $13.4 million, which would significantly bolster its financial resources for future initiatives.
- Use of Funds: The company intends to allocate a portion of the net proceeds towards potential strategic product acquisitions, with the remainder earmarked for working capital, research and development, and general corporate purposes, reflecting a proactive approach to growth.
- Market Compliance: The securities offering is conducted under Section 4(a)(2) of the Securities Act of 1933, remaining unregistered in the U.S., which highlights the company's cautious stance on compliance while also limiting the liquidity of the securities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RDHL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RDHL
About RDHL
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RedHill Biopharma Enters ADS Purchase Agreement
- Offering Size: RedHill Biopharma announced the issuance of 8.57 million American depositary shares (ADS), with each ADS representing 10,000 ordinary shares, expected to generate approximately $6 million in revenue, thereby strengthening its capital structure for future growth.
- Subscription Terms: The purchase price for each ADS and accompanying Series A-1 and A-2 warrants is set at $0.70, with the exercise price for Series A-1 warrants at $0.86 and Series A-2 at $0.70, reflecting the company's confidence in future stock performance.
- Warrant Details: Series A-1 warrants are immediately exercisable with a five-year term, while Series A-2 warrants are also immediately exercisable but with an 18-month term, providing flexible financing options to support the company's strategic objectives.
- Use of Proceeds: The company intends to allocate a portion of the net proceeds for potential strategic product acquisitions, with the remainder designated for working capital, research and development, and general corporate purposes, indicating a proactive approach to future growth.
See More
RedHill Biopharma Completes Private Placement Financing
- Financing Scale: RedHill Biopharma has entered into a private placement for 8,571,429 American Depositary Shares (ADSs) at a purchase price of $0.70 per ADS, expecting to raise approximately $6 million, indicating strong market interest in the company.
- Potential Revenue: If the Series A-1 and A-2 warrants are fully exercised, RedHill could secure an additional $13.4 million, which would significantly bolster its financial resources for future initiatives.
- Use of Funds: The company intends to allocate a portion of the net proceeds towards potential strategic product acquisitions, with the remainder earmarked for working capital, research and development, and general corporate purposes, reflecting a proactive approach to growth.
- Market Compliance: The securities offering is conducted under Section 4(a)(2) of the Securities Act of 1933, remaining unregistered in the U.S., which highlights the company's cautious stance on compliance while also limiting the liquidity of the securities.
See More
RedHill Biopharma Receives FDA Rare Pediatric Disease Designation for Opaganib
- FDA Designation Progress: RedHill Biopharma's opaganib has received FDA's rare pediatric disease designation for neuroblastoma treatment, which provides a Priority Review Voucher subject to certain conditions, indicating the company's potential in pediatric oncology.
- Orphan Drug Status: Opaganib has also received Orphan Drug designation from the FDA for neuroblastoma and cholangiocarcinoma, enhancing its market appeal and potentially accelerating clinical development, thereby strengthening the company's competitive position in oncology.
- Clinical Research Readiness: The company is prepared to submit the Phase 1 chemoradiotherapy study protocol for opaganib to the FDA-IND, demonstrating a proactive approach in advancing clinical trials, which may pave the way for future drug approval.
- Stock Price Volatility: In pre-market trading on NasdaqCM, RedHill's shares fell by 21.57% to $0.80, reflecting a negative market reaction to the news, which could impact the company's financing and future development plans.
See More
FDA Grants Rare Pediatric Disease Designation to Opaganib for Neuroblastoma Treatment
- Rare Pediatric Disease Designation: The FDA has granted Opaganib a rare pediatric disease designation for neuroblastoma treatment, providing a Priority Review Voucher (PRV) that facilitates accelerated drug development and review processes, thereby enhancing market competitiveness.
- Significant Market Potential: The neuroblastoma market is projected to reach approximately $3.5 billion by 2032, and Opaganib, as a novel small molecule drug, is poised to capture a significant share in this rapidly growing market if approved.
- Clinical Data Support: Positive effects of Opaganib as a potential add-on therapy were presented at the 2026 American Association for Cancer Research Annual Meeting, indicating its potential to improve treatment outcomes for patients with neuroblastoma and triple-negative breast cancer.
- Strategic Partnerships: Ongoing discussions between RedHill Biopharma and Penn State University, along with the Beat Childhood Cancer consortium, aim to further advance the development of Opaganib, demonstrating the company's strong commitment to enhancing pediatric cancer treatment.
See More
FDA Grants Rare Pediatric Disease Designation to Opaganib for Neuroblastoma
- Rare Disease Designation: The FDA has granted Opaganib a rare pediatric disease designation for neuroblastoma, which provides a Priority Review Voucher (PRV) that can accelerate drug development and review processes, thereby enhancing its market competitiveness.
- Significant Market Potential: The neuroblastoma market is projected to reach approximately $3.5 billion by 2032, and Opaganib, as a novel small molecule drug, is expected to capture a significant share if approved in this rapidly growing market.
- Clinical Data Support: Positive effects of Opaganib as a potential add-on therapy in high-risk neuroblastoma models were presented at the 2026 American Association for Cancer Research Annual Meeting, indicating its potential to improve treatment outcomes for patients.
- Strategic Collaboration Outlook: RedHill aims to advance Opaganib's development through ongoing discussions with Penn State University and the Beat Childhood Cancer consortium, demonstrating the company's long-term commitment and strategic positioning in pediatric cancer treatment.
See More
RedHill Biopharma Initiates Enforcement Proceedings in Korea
- Court Judgment Enforcement: RedHill Biopharma has initiated enforcement proceedings in Korea against Kukbo Co. Ltd., concerning a $10.9 million judgment from the New York Supreme Court, marking a significant step in the company's international legal efforts and potentially laying the groundwork for future asset recovery.
- Legal Fees Confirmation: The New York court's ruling includes approximately $8.9 million in principal and $1.95 million in legal fees, both of which are now final, demonstrating RedHill's legal victory and enhancing its financial stability.
- Asset Protection Measures: RedHill has secured a court attachment in Korea against Kukbo to prevent asset disposal prior to judgment enforcement, a strategic move that helps ensure the potential recovery of awarded damages.
- Awaiting Further Developments: The company is currently awaiting Kukbo's response in the Korean proceedings and further scheduling by the court, and while there are no guarantees regarding the timing or amount of recovery, this process reflects RedHill's commitment to protecting its interests.
See More
RedHill Biopharma Enters ADS Purchase Agreement
- Offering Size: RedHill Biopharma announced the issuance of 8.57 million American depositary shares (ADS), with each ADS representing 10,000 ordinary shares, expected to generate approximately $6 million in revenue, thereby strengthening its capital structure for future growth.
- Subscription Terms: The purchase price for each ADS and accompanying Series A-1 and A-2 warrants is set at $0.70, with the exercise price for Series A-1 warrants at $0.86 and Series A-2 at $0.70, reflecting the company's confidence in future stock performance.
- Warrant Details: Series A-1 warrants are immediately exercisable with a five-year term, while Series A-2 warrants are also immediately exercisable but with an 18-month term, providing flexible financing options to support the company's strategic objectives.
- Use of Proceeds: The company intends to allocate a portion of the net proceeds for potential strategic product acquisitions, with the remainder designated for working capital, research and development, and general corporate purposes, indicating a proactive approach to future growth.
See More
RedHill Biopharma Completes Private Placement Financing
- Financing Scale: RedHill Biopharma has entered into a private placement for 8,571,429 American Depositary Shares (ADSs) at a purchase price of $0.70 per ADS, expecting to raise approximately $6 million, indicating strong market interest in the company.
- Potential Revenue: If the Series A-1 and A-2 warrants are fully exercised, RedHill could secure an additional $13.4 million, which would significantly bolster its financial resources for future initiatives.
- Use of Funds: The company intends to allocate a portion of the net proceeds towards potential strategic product acquisitions, with the remainder earmarked for working capital, research and development, and general corporate purposes, reflecting a proactive approach to growth.
- Market Compliance: The securities offering is conducted under Section 4(a)(2) of the Securities Act of 1933, remaining unregistered in the U.S., which highlights the company's cautious stance on compliance while also limiting the liquidity of the securities.
See More
RedHill Biopharma Receives FDA Rare Pediatric Disease Designation for Opaganib
- FDA Designation Progress: RedHill Biopharma's opaganib has received FDA's rare pediatric disease designation for neuroblastoma treatment, which provides a Priority Review Voucher subject to certain conditions, indicating the company's potential in pediatric oncology.
- Orphan Drug Status: Opaganib has also received Orphan Drug designation from the FDA for neuroblastoma and cholangiocarcinoma, enhancing its market appeal and potentially accelerating clinical development, thereby strengthening the company's competitive position in oncology.
- Clinical Research Readiness: The company is prepared to submit the Phase 1 chemoradiotherapy study protocol for opaganib to the FDA-IND, demonstrating a proactive approach in advancing clinical trials, which may pave the way for future drug approval.
- Stock Price Volatility: In pre-market trading on NasdaqCM, RedHill's shares fell by 21.57% to $0.80, reflecting a negative market reaction to the news, which could impact the company's financing and future development plans.
See More
FDA Grants Rare Pediatric Disease Designation to Opaganib for Neuroblastoma Treatment
- Rare Pediatric Disease Designation: The FDA has granted Opaganib a rare pediatric disease designation for neuroblastoma treatment, providing a Priority Review Voucher (PRV) that facilitates accelerated drug development and review processes, thereby enhancing market competitiveness.
- Significant Market Potential: The neuroblastoma market is projected to reach approximately $3.5 billion by 2032, and Opaganib, as a novel small molecule drug, is poised to capture a significant share in this rapidly growing market if approved.
- Clinical Data Support: Positive effects of Opaganib as a potential add-on therapy were presented at the 2026 American Association for Cancer Research Annual Meeting, indicating its potential to improve treatment outcomes for patients with neuroblastoma and triple-negative breast cancer.
- Strategic Partnerships: Ongoing discussions between RedHill Biopharma and Penn State University, along with the Beat Childhood Cancer consortium, aim to further advance the development of Opaganib, demonstrating the company's strong commitment to enhancing pediatric cancer treatment.
See More
FDA Grants Rare Pediatric Disease Designation to Opaganib for Neuroblastoma
- Rare Disease Designation: The FDA has granted Opaganib a rare pediatric disease designation for neuroblastoma, which provides a Priority Review Voucher (PRV) that can accelerate drug development and review processes, thereby enhancing its market competitiveness.
- Significant Market Potential: The neuroblastoma market is projected to reach approximately $3.5 billion by 2032, and Opaganib, as a novel small molecule drug, is expected to capture a significant share if approved in this rapidly growing market.
- Clinical Data Support: Positive effects of Opaganib as a potential add-on therapy in high-risk neuroblastoma models were presented at the 2026 American Association for Cancer Research Annual Meeting, indicating its potential to improve treatment outcomes for patients.
- Strategic Collaboration Outlook: RedHill aims to advance Opaganib's development through ongoing discussions with Penn State University and the Beat Childhood Cancer consortium, demonstrating the company's long-term commitment and strategic positioning in pediatric cancer treatment.
See More
RedHill Biopharma Initiates Enforcement Proceedings in Korea
- Court Judgment Enforcement: RedHill Biopharma has initiated enforcement proceedings in Korea against Kukbo Co. Ltd., concerning a $10.9 million judgment from the New York Supreme Court, marking a significant step in the company's international legal efforts and potentially laying the groundwork for future asset recovery.
- Legal Fees Confirmation: The New York court's ruling includes approximately $8.9 million in principal and $1.95 million in legal fees, both of which are now final, demonstrating RedHill's legal victory and enhancing its financial stability.
- Asset Protection Measures: RedHill has secured a court attachment in Korea against Kukbo to prevent asset disposal prior to judgment enforcement, a strategic move that helps ensure the potential recovery of awarded damages.
- Awaiting Further Developments: The company is currently awaiting Kukbo's response in the Korean proceedings and further scheduling by the court, and while there are no guarantees regarding the timing or amount of recovery, this process reflects RedHill's commitment to protecting its interests.
See More
